Organic Active Ingredients TRIZ Cases

A bispecific engager links dendritic cells to tumor markers to boost anti-cancer immunity.

RNA aptamer targets CEA linkage region, resolving antibody immunogenicity and stability issues while inhibiting liver metastasis.

Nano-dry-melting aqueous nanoparticle suspensions creates amorphous solid dispersions without organic solvents or thermal degradation.

Mesoporous silica particles sequester pathogenic proteins in cerebrospinal fluid, delaying neurodegenerative disease progression and increasing survival rates.

Optimizing the tip diameter to 20 µm and aspect ratio to 1–5 maintains structural integrity while enabling efficient drug delivery.

Homogeneous phospholipid bilayers catalytically promote protein refolding and increase stability.

Formula I and II compounds mitigate radiation-induced apoptosis through cellular uptake saturation.

Biguanide dimers chelate mitochondrial copper to inhibit alpha-ketoglutarate production, resolving moderate potency limits in inflammatory disease treatment.

Dual inhibition of bromodomain and DNA methylation pathways overcomes acquired resistance in cancer therapy, restoring drug efficacy.

Fluorinated benzene structure enhances solubility and metabolic stability while reducing toxicity in cancer therapy.

Menthyl carbamate compounds lighten skin and hair without cytotoxicity or instability issues associated with traditional hydroquinone agents.

Hexylene glycol suspends mometasone furoate to reduce skin irritancy while maintaining therapeutic efficacy and hydration.

Probiotic bacteria induce split anergy in natural killer cells, balancing enhanced anti-tumor immunity with reduced unwanted inflammation.

Dual Factor XIa and kallikrein inhibitors address complex blood coagulation pathways to prevent thrombosis.

Conjugating GBS serotype III oligosaccharides with carrier proteins creates immunogenic compositions.

A coenzyme Q10 microemulsion uses specific emulsifiers to form a thermodynamically stable system with 20-80 nm particles.

Pyridine macrocycle compounds inhibit apoptosis signal-regulating kinase 1 to treat neurodegenerative and cardiovascular disorders.

Consolidating multiple coating steps into one fluid bed coater improves mesalamine pellet reproducibility.

Covalent inhibitors bind cysteine residues at position 12, locking the switch II domain to overcome low inhibition effectiveness of small molecules.

A pharmaceutical composition containing a specific imidazopyrazinone compound disrupts YAP/TAZ-TEAD protein interactions.

Anti-protease nexin-1 antibodies neutralize the anticoagulant inhibitor to enhance thrombin generation and bypass factor VIII resistance.

A glycogen and polysaccharide mixture provides sustained active ingredient release through diffusion and erosion mechanisms.

Novel cationic lipids form lipid nanoparticles to protect nucleic acids from plasma nuclease digestion while facilitating efficient intracellular delivery.

CRISPR-mediated PTGIR knockout in CD8 T-cells eliminates prostacyclin signaling, restoring anti-tumor activity suppressed by tumor-derived prostanoids.

4-Alkenyl and 4-alkynyl phenethylamine derivatives interact with serotonin 5-HT2A receptors to induce psychoactive effects.

Formula I compounds reduce viral load by modifying chemical structures to optimize antiviral activity while maintaining patient safety.

Optimized crystallization parameters transform unstable ruxolitinib free base into defined dihydrate crystals, resolving purity and hygroscopicity trade-offs.

Modified ganciclovir derivatives reduce toxic side effects while maintaining antiviral efficacy against HCMV in transplant patients.

Increasing miR-18b expression suppresses apoptosis and recovers calcium signaling to address underlying dysregulation in gene mutation-induced muscle diseases.

Polydeoxyribonucleotides treat inflammatory bowel disease by activating A2A receptors, reducing side effects from conventional therapies.

Novel bicyclic tetrahydrofuran derivatives protect chain-terminating nucleotides from enzymatic excision.

Formula I compounds selectively inhibit CDK19 over CDK8, resolving the contradiction between anti-cancer efficacy and gastrointestinal side effects.

Dual-sensitive vesicles eliminate excess hydrogen peroxide during glucose oxidation, preventing localized inflammation while delivering insulin.

Lipid-modified tc-DNA oligomers bind serum albumin to enhance bioavailability and reduce toxicity while promoting exon 51 skipping.